2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

human NK cells

" in MedChemExpress (MCE) Product Catalog:

47

Inhibitors & Agonists

6

Peptides

23

Inhibitory Antibodies

4

Natural
Products

6

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-113008B
    trans-Urocanic acid

    (E)-Urocanic acid; trans-UCA

    		 Endogenous Metabolite Inflammation/Immunology
    trans-urocanic acid (trans-UCA), a natural epidermal constituent, inhibits human natural killer cell (NK) activity in vitro. trans-urocanic acid is active in regulating an immune function .
    trans-Urocanic acid
  • HY-120350
    BI-1347
    5+ Cited Publications

    		 CDK Cancer
    BI-1347 is an orally active, selective and potent CDK8 inhibitor (IC50=1.1 nM). BI-1347 shows anti-tumoral activity .
    BI-1347
  • HY-P5307
    Peptide A5K

    INF7-A5K-TAT

    		 Biochemical Assay Reagents Others
    Peptide A5K (INF7-A5K-TAT) is an amphiphilic peptide derived from the HA2-TAT fusion scaffold. Peptide A5K can non-covalently bind to CRISPR ribonucleoproteins and efficiently deliver them to cells, such as primary human T cells, B cells, and NK cells. Peptide A5K enables low-toxicity, precise, and multiplex genome editing, holding great application potential in the field of cell therapy .
    Peptide A5K
  • HY-160041A
    Olaptesed pegol sodium

    NOX-A12 sodium

    		 CXCR Cancer
    Olaptesed pegol (NOX-A12) sodium is a L-oligoribonucleotide aptamer targeting CXCL12 based on a pegylated structure. Olaptesed pegol sodium neutralizes CXCL12, and CXCL12 inhibition mobilizes chronic lymphocytic leukemia cells into the circulation and prevents their homing into the protective microenvironment. Olaptesed pegol sodium can enhances the infiltration of human primary T cells and NK cells and inhibit tumor growth companied with anti-PD-1 antibody. Olaptesed pegol sodium can be used for researches of colon cancer and lymphocytic leukemia .
    Olaptesed pegol sodium
  • HY-160041
    Olaptesed pegol

    NOX-A12

    		 CXCR Cancer
    Olaptesed pegol (NOX-A12) is a L-oligoribonucleotide aptamer targeting CXCL12 based on a pegylated structure. Olaptesed pegol neutralizes CXCL12, and CXCL12 inhibition mobilizes chronic lymphocytic leukemia cells into the circulation and prevents their homing into the protective microenvironment. Olaptesed pegol can enhances the infiltration of human primary T cells and NK cells and inhibit tumor growth companied with anti-PD-1 antibody. Olaptesed pegol can be used for researches of colon cancer and lymphocytic leukemia .
    Olaptesed pegol
  • HY-P991149
    Nesfrotamig

    YH32367; ABL105

    		 TNF Receptor Cancer
    Nesfrotamig (YH32367; ABL105) is a bispecific activator targeting HER2 and 4-1BB. The Kd values of Nesfrotamig for human HER2 and human 4-1BB are 0.48 nM and 3.36 nM, respectively. By blocking tumor cell growth signals, activating HER2-dependent local 4-1BB in tumors to maintain T cell survival, and inducing NK cell-mediated antibody-dependent cellular cytotoxicity, Nesfrotamig enhances the cytotoxicity and tumor infiltration ability of immune cells. Nesfrotamig promotes the generation of tumor-specific memory T cells, drives T cell-mediated tumor lysis, exhibits significant anti-tumor efficacy against both HER2-positive and HER2-low-expressing tumors, and shows synergistic activity when combined with anti-PD-1 antibodies. In cynomolgus monkey studies, Nesfrotamig demonstrates good safety and is suitable for research related to HER2-positive and HER2-low-expressing tumors .
    Nesfrotamig
  • HY-P99661
    Inbakicept
    2 Publications Verification

    		 Interleukin Related Cancer
    Inbakicept is a dimeric human IL-15 receptor alpha (IL-15 Ra) sushi domain/human IgG1 Fc fusion protein and is an IL-15 superagonist complex. Inbakicept is able to form complex N-803 (Nogapendekin alfa inbakicept) with the IL-15 antibody Nogapendekin alfa in a 1:2 ratio. N-803 mimics the function of IL-15 and amplifies anti-CD20 mAb-mediated NK cell responses and antibody-dependent cellular cytotoxicity (ADCC). N-803 also increases degranulation and IFNγ production in cells .
    Inbakicept
  • HY-P99291
    Etaracizumab

    LM609; MEDI-522

    		 Integrin Apoptosis Akt Cancer
    Etaracizumab (LM 609) is an αvβ3 integrin IgG mAb. Etaracizumab is developed to target αvβ3+ cancer cells via NK cell-mediated cytotoxicity. Etaracizumab sterically hinders access of large ligands to the RGD-binding pocket, without obstructing it. Etaracizumab decreases p-Akt in vitro. Etaracizumab can decrease cancer proliferation and invasion. Etaracizumab induces tumor cell apoptosis, and inhibition ofαvβ3-mediated cell adhesion, endothelial cell migration and osteoclast-mediated bone resorption. Etaracizumab can be studied in anti-tumor research against cancers such as ovarian cancer, metastatic melanoma as well as advanced solid tumors. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Etaracizumab
  • HY-P990017
    Englumafusp alfa

    CD19-4-1BBL; RO7227166; RG6076

    		 CD19 Cancer
    Englumafusp alfa (CD19-4-1BBL; RO7227166) is a fusion construct comprised of a CD19-specific antibody domain fused to a trimerized extracellular domains of human 41BBL. Englumafusp alfa promotes CD19-specific 4-1BB cross-linking on the surface of T and NK cells .
    Englumafusp alfa
  • HY-153793
    Alcudacigib

    DGKζ-IN-1

    		 DGK IFNAR Interleukin Related ERK Cancer
    Alcudacigib (ASP1570; DGKζ-IN-1) is an orally active diacylglycerol kinase ζ (DGKζ) inhibitor, with an IC50 of 4.7 nM against human DGKζ and an IC50 of 3.0 nM against mouse DGKζ. Alcudacigib selectively inhibits the kinase activity of DGKζ and induces proteasome-dependent degradation of DGKζ protein. Alcudacigib enhances the anti-tumor functions of T cells and NK cells. Alcudacigib can be used for the research of advanced/metastatic solid tumors .
    Alcudacigib
  • HY-P991201
    REGN-7257

    		Interleukin Related Inflammation/Immunology
    REGN-7257 is a humanized monoclonal antibody targeting IL2RG. REGN-7257 blocks the signal transduction induced by common gamma chain (γc) cytokines via the IL2RG chain of the γc cytokine receptor complex. REGN-7257 is applicable for research on immune-mediated diseases and T cell-mediated diseases . Its corresponding isotype control is Human IgG4 kappa, Isotype Control (HY-P99003).
    REGN-7257
  • HY-107691
    GR 159897

    		Neurokinin Receptor Neurological Disease Endocrinology Cancer
    GR 159897 is a highly potent, selective, competitive, brain-penetrated non-peptide neurokinin 2 (NK2) receptor antagonist. GR 159897 has little or no affinity for NK1 and NK3 receptors. GR 159897 inhibits binding of [ 3H]GR100679 to human NK2 (hNK2)-CHO cells and rat colon membranes with pKis of 9.51 and 10, respectively. Antagonizes bronchoconstriction. Anxiolytic-like and anti-tumor effects .
    GR 159897
  • HY-P99759
    Nogapendekin alfa (his tag)

    IL-15N72D

    		 Interleukin Related Inflammation/Immunology Cancer
    Nogapendekin alfa (his tag), a soluble protein subunit of a human interleukin (IL)-15 variant, is a superagonist of IL-15. Nogapendekin alfa (his tag) promotes the proliferation and viability of immune cells. Nogapendekin alfa (his tag) combines with Inbakicept (HY-P99661) at a ratio of 2:1, to form N-803 (Nogapendekin alfa inbakicept), an IL-15 cytokine antibody fusion protein. N-803 reduces tumor burden by activation of NK cells and CD8 + T cells .
    Nogapendekin alfa (his tag)
  • HY-153793A
    Alcudacigib TFA

    DGKζ-IN-1 TFA

    		 DGK IFNAR Interleukin Related ERK Cancer
    Alcudacigib (ASP1570; DGKζ-IN-1) TFA is an orally active diacylglycerol kinase ζ (DGKζ) inhibitor, with an IC50 of 4.7 nM against human DGKζ and an IC50 of 3.0 nM against mouse DGKζ. Alcudacigib TFA selectively inhibits the kinase activity of DGKζ and induces proteasome-dependent degradation of DGKζ protein. Alcudacigib TFA enhances the anti-tumor functions of T cells and NK cells. Alcudacigib TFA can be used for the research of advanced/metastatic solid tumors .
    Alcudacigib TFA
  • HY-150749A
    ODN D-SL03 sodium

    		IFNAR Cancer
    ODN D-SL03 sodium is a C class CpG oligonucleotides, and can induce stimulate PBMCs to produce high level of IFN-α. ODN D-SL03 sodium can activate human B cells, NK cells and mononuclear cells and up-regulate expression of CD80, CD86 and HLA-DR on the surface of subsets in human PBMCs. ODN D-SL03 sodium also can inhibit the growth of the tumor. ODN D-SL03 sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3' .
    ODN D-SL03 sodium
  • HY-P10978
    NK224

    		PD-1/PD-L1 Cancer
    NK224 is a peptide-based radiotracer targeting human PD-L1, with dual-radionuclide ( 68Ga and 18F) labeling compatibility enabled by the NOTA chelator. NK224 exhibits high binding affinity to PD-L1, with an IC50 value of 2.45 nM. NK224 visualizes intrapatient tumor heterogeneity and dynamically monitors PD-L1 target occupancy during immunotherapy. NK224 can be used for the study of non-small cell lung cancer (NSCLC) .
    NK224
  • HY-P991382
    SAR-439459

    		TGF-β Receptor Cancer
    SAR-439459 is a human monoclonal antibody (mAb) targeting TGFB1/TGFβ-1. SAR-439459 blocks TGFβ-mediated pSMAD signaling, and suppression of T cells and NK cells. SAR-439459 has anti-tumor activity .
    SAR-439459
  • HY-P991000
    Imneskibart

    AU-007; BD-8; BDG8

    		 Interleukin Related Cardiovascular Disease Inflammation/Immunology Cancer
    Imneskibart (AU-007) is a human monoclonal antibody that binds to the CD25-binding epitope of interleukin-2 (IL-2), blocking the binding of IL-2 to the trimeric IL-2 receptor while retaining the ability to bind to the dimeric IL-2 receptor. Imneskibart expands effector T cell and NK cell populations, reduces regulatory T cells, increases the effector T cell/regulatory T cell ratio, and alleviates vascular leakage. Imneskibart can be used in research related to melanoma and non-small cell lung cancer. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Imneskibart
  • HY-P991543
    BTI-322

    		CD2 Inflammation/Immunology Cancer
    BTI-322 is a human IgG1κ antibody directed against the CD2 antigen on T cells and NK cells. BTI-322 can block primary and memory alloantigen proliferative responses in vitro. BTI-322 recognizes over 90% of E-rosette-forming peripheral blood lymphocytes and T-cell leukemias. BTI-322 has immunosuppressive activity. BTI-322 effectively inhibits T cell responses in vitro to allogeneic cells. BTI-322 can be used as a T-cell deplting agent. BTI-322 can be studied in research for renal allograft rejection and steroid-refractory acute graft-versus-host disease .
    BTI-322
  • HY-18626
    NK 314

    		Topoisomerase Cancer
    NK 314 is an inhibitor for topoisomerase IIα, which generates the break of DNA double-strand. NK 314 arrests the cell cycle at G2 phase in human acute myeloid leukemia cells, inhibits the proliferation of CEM with IC90 of 55 nM .
    NK 314
  • HY-P11340
    VMAPRTLFL

    		MHC Infection Inflammation/Immunology
    VMAPRTLFL is a 9-mer peptide derived from the signal peptide of HLA-G and can serve as a peptide ligand for HLA-E. VMAPRTLFL plays a crucial role in regulating the functions of adaptive natural killer (NK) cells. Specifically, VMAPRTLFL enriches FcεRγ - adaptive NK cells, upregulates the expression of CD25, and enhances their proliferative activity, antibody-dependent cellular cytotoxicity (ADCC), and IFN-γ release. VMAPRTLFL can be used in research related to human cytomegalovirus (HCMV) infection, transplant rejection, and pregnancy immunity .
    VMAPRTLFL
  • HY-P990031
    Dargistotug

    M-6223

    		 Transmembrane Glycoprotein Inflammation/Immunology Cancer
    Dargistotug (M-6223) is a fully human IgG1 monoclonal antibody targeting TIGIT (T cell immune receptor with Ig domain and ITIM). TIGIT is an inhibitory immune checkpoint that promotes NK cell depletion and reduces the secretion of cytokines by binding to CD155 and other antibodies. It can also directly or indirectly inhibit effector T cells and upregulate Tregs cells, thereby exerting immunosuppression. Function .
    Dargistotug
  • HY-P5307A
    Peptide A5K acetate

    INF7-A5K-TAT acetate

    		 Biochemical Assay Reagents Others
    Peptide A5K (INF7-A5K-TAT) acetate is an amphiphilic peptide derived from the HA2-TAT fusion scaffold. Peptide A5K acetate can non-covalently bind to CRISPR ribonucleoproteins and efficiently deliver them to cells, such as primary human T cells, B cells, and NK cells. Peptide A5K acetate enables low-toxicity, precise, and multiplex genome editing, holding great application potential in the field of cell therapy .
    Peptide A5K acetate
  • HY-P991475
    MG-1131

    		Transmembrane Glycoprotein NF-κB IFNAR Cancer
    MG-1131 is a human monoclonal antibody (mAb) targeting TIGIT. MG-1131 activates NF-κB signaling in T cells and enhances NK-mediated tumor killing activity in a PVR-dependent manner. MG-1131 blocks TIGIT to increase IFN-γ secretion. MG-1131 can be used in anti-tumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
    MG-1131
  • HY-P990719
    Efbalropendekin alfa

    XmAb24306

    		 Interleukin Related Inflammation/Immunology Cancer
    Efbalropendekin Alfa (XmAb24306) is an IL-15/IL-15 receptor alpha complex fused to a heterodimeric Fc domain (IL15/IL15Rα-Fc). Efbalropendekin Alfa increases direct and antibody-dependent cellular cytotoxicity (ADCC)-mediated human natural killer (NK) cell cytotoxicity in vitro .
    Efbalropendekin alfa
  • HY-P10795
    NK-2

    Antibiotic NK 2

    		 Parasite Bacterial Fungal Infection
    NK-2 (Antibiotic NK 2), a shortened linear amphipathic NK-Lysin analog (comprising residues 39 to 65 of NK-lysin), is an antimicrobial peptide that exhibits potent activities against trypanosoma cruzi, Candida albicans, gram-positive and gram-negative bacteria. NK-2 can kill trypanosomes residing inside the human glioblastoma cell line 86HG39, left the host cells apparently unharmed .
    NK-2
  • HY-P11298
    d-T101 peptide

    		Caspase Apoptosis JNK p38 MAPK Interleukin Related IFNAR Inflammation/Immunology Cancer
    d-T101 peptide, a human hormone-peptide, is a T1/ST2 receptor ligand. d-T101 peptide binds to the T1/ST2 receptor and activates caspases 8, 9 and 3 mediated apoptosis, together with activation of JNKinase and p38 MAPKinase. d-T101 peptide also changes Golgi structural with function loss and downregulation of the endoplasmic reticulum (ER) stress repair mechanism. d-T101 peptide has immunostimulatory and anticancer activity, selectively induces apoptosis in proliferating cancer cells and increases IL-2 and IFN-γ expression as well as the recruitment of NK cells and M1 macrophages to the tumor site .
    d-T101 peptide
  • HY-176546
    NK3R-IN-2

    		Neurokinin Receptor Endocrinology
    NK3R-IN-2 is an orally active NK3R inhibitor with an IC50 of 330.50 nM for human NK3R. NK3R-IN-2 can pass through the blood-brain barrier. NK3R-IN-2 has excellent NK3R binding affinity (IC50 = 87.31 nM) in CHO-K1 cells. NK3R-IN-2 effectively inhibits the level of luteinizing hormone (LH). NK3R-IN-2 can be used for research on hormone related conditions .
    NK3R-IN-2
  • HY-10049A
    CP 122721 hydrochloride

    		Neurokinin Receptor Neurological Disease
    CP 122721 hydrochloride is a potent, non-peptide and selective nonpeptide neurokinin NK1 antagonist, with a pIC50 of 9.8 for human NK1 receptor expressed in IM-9 cells. CP 122721 hydrochloride exhibits anxiolytic and antidepressant-like effects .
    CP 122721 hydrochloride
  • HY-119552
    Acetylaszonalenin

    LL-S490β

    		 Endogenous Metabolite Neurokinin Receptor Neurological Disease
    Acetylaszonalenin, a prenylated indole derivative, is a fungal metabolite.Acetylaszonalenin is a potent neurokinin-1 (NK1) receptor antagonist. Acetylaszonalenin shows inhibition of [ 3H]-SP binding to human astrocytoma cells with a Ki of 170 μM .
    Acetylaszonalenin
  • HY-113008BR
    trans-Urocanic acid (Standard)

    (E)-Urocanic acid (Standard); trans-UCA (Standard)

    		 Endogenous Metabolite Reference Standards Inflammation/Immunology
    trans-Urocanic acid (Standard) is the analytical standard of trans-Urocanic acid. This product is intended for research and analytical applications. trans-urocanic acid (trans-UCA), a natural epidermal constituent, inhibits human natural killer cell (NK) activity in vitro. trans-urocanic acid is active in regulating an immune function .
    trans-Urocanic acid (Standard)
  • HY-174630
    Human IL18R1 mRNA

    		mRNA Inflammation/Immunology
    Human IL18R1 mRNA encodes the human interleukin 18 receptor 1 (IL18R1) protein, a cytokine receptor that belongs to the interleukin 1 receptor family. IL18R1 is essential for IL18 mediated signal transduction. IFN-alpha and IL12 are reported to induce the expression of this receptor in NK and T cells.
    Human IL18R1 mRNA
  • HY-150749
    ODN D-SL03

    		IFNAR Inflammation/Immunology Cancer
    ODN D-SL03 is a C class CpG oligonucleotides, can induce stimulate PBMCs to produce high level of IFN-α. ODN D-SL03 can activate human B cells, NK cells and mononuclear cells and up-regulate expression of CD80, CD86 and HLA-DR on the surface of subsets in human PBMCs. ODN D-SL03 also can inhibit the growth of the tumor. ODN D-SL03 sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3' .
    ODN D-SL03
  • HY-P991270
    MT204

    		Interleukin Related Inflammation/Immunology
    MT204 is a humanized IgG1 antibody inhibitor targeting IL-2 of human and rhesus monkey origin. MT204 prevents soluble IL-2 from binding to intermediate-affinity IL-2 receptors and blocks CD25-bound IL-2 on high-affinity IL-2 receptors. MT204 has potently anti-proliferative activity with NKL cells and primary NK cells. MT204 has good tolerability and potent immunosuppressive activity in allogeneic skin graft model of rhesus monkey, promising for immunosuppressive and anti-proliferative therapy .
    MT204
  • HY-P992406
    MEDI-3622

    		MMP IFNAR Cancer
    MEDI-3622 is a human monoclonal antibody against ADAM17. MEDI-3622 blocks the ADAM17-mediated shedding of CD16A and CD62L on NK cells, and binds with high specificity to a surface loop unique to the metalloprotease catalytic domain of ADAM17. MEDI-3622 enhances IFNγ production by NK cells when they bind to antibody-coated tumor cells. MEDI-3622 can be used in the research of ovarian cancer, Burkitt lymphoma, head and neck cancer, and colorectal cancer .
    MEDI-3622
  • HY-P992201
    Anti-CD160 Antibody (MAT 302)

    CL1-R2

    		 MHC Apoptosis IFNAR TNF Receptor Interleukin Related Akt mTOR Cardiovascular Disease Neurological Disease Cancer
    Anti-CD160 Antibody (MAT 302) (CL1-R2) is a human monoclonal antibody targeting CD160. Anti-CD160 Antibody (MAT 302) blocks the CD160-HVEM protein interaction, inhibits FGF2-mediated renal tubular vascular growth, and induces endothelial cell apoptosis. Anti-CD160 Antibody (MAT 302) targets CD160 on neovascularization to exert anti-angiogenic and vascular normalization effects, trigger the production of IFN-γ, TNF and IL-6 by NK cells, and enhance glucose metabolism of NK cells through the AKT/mTOR/s6k signaling pathway. Anti-CD160 Antibody (MAT 302) reduces vascular density, normalizes remaining tumor blood vessels, and inhibits tumor growth in melanoma-bearing mice. Anti-CD160 Antibody (MAT 302) can be used in research related to neovascularization, proliferative diabetic retinopathy, and melanoma .
    Anti-CD160 Antibody (MAT 302)
  • HY-N9554
    WIN-64821

    		Neurokinin Receptor Endogenous Metabolite Calcium Channel Neurological Disease Inflammation/Immunology
    WIN-64821 is a secondary metabolite produced by Aspergillus species, and acts as a Neurokinin Receptor antagonist. The Ki values of WIN-64821 for NK1, NK2 and NK3 receptors are 0.24 (human astrocytoma cells), 0.26 (rat duodenum) and 15.2 (guinea pig forebrain) μM, respectively. WIN-64821 inhibits apamin-induced contraction of rat vas deferens, blocks substance P-induced contraction of guinea pig ileum and Ca 2+ efflux in human astrocytoma cells. WIN-64821 is applicable to analgesic and anti-inflammatory research .
    WIN-64821
  • HY-174621
    Human IL21R mRNA

    		mRNA Inflammation/Immunology
    Human IL21R mRNA encodes the human interleukin 21 receptor (IL21R) protein, a cytokine receptor for interleukin 21 (IL21). IL21R can transduce the growth promoting signal of IL21, and is important for the proliferation and differentiation of T cells, B cells, and natural killer (NK) cells.
    Human IL21R mRNA
  • HY-P992455
    SAR442085

    		CD38 Fc Receptor (FcR) Apoptosis Cancer
    SAR442085 is an Fc-engineered anti-CD38 monoclonal antibody with a Kd of 0.2 nM for human CD38. SAR442085 inhibits CD38, induces apoptosis, and triggers antibody-dependent cellular cytotoxicity and phagocytosis in CD38-expressing tumor cells. SAR442085 binds allelic variants of FcγRIIa and FcγRIIIa, enhances NK cell activation, degranulation and cytokine secretion, and exerts anti-tumor activity in human Fc receptor transgenic mice. SAR442085 can be used in the research of multiple myeloma .
    SAR442085
  • HY-P992030
    FB102

    		Transmembrane Glycoprotein Inflammation/Immunology
    FB102 is an anti-human CD122 (IL-2Rβ) monoclonal antibody with selective activity. FB102 blocks the proliferation and activation of pathogenic NK cells and specific T cell subsets induced by IL-2 and IL-15, without affecting the proliferation of regulatory T cells. FB102 inhibits IL-2/IL-15-induced activation of CD4+ and CD8+ T cells in in vitro disease models. FB102 is applicable to research related to celiac disease .
    FB102
  • HY-P992450
    REGN6569

    		TNF Receptor Cancer
    REGN6569 is a fully human IgG1 monoclonal antibody targeting glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR) with high specificity for GITR. REGN6569 exerts stronger in vitro antibody-dependent cell-mediated cytotoxicity (ADCC) against regulatory T cells expressing GITR. REGN6569 selectively depletes regulatory T cells via antibody-dependent cell-mediated cytotoxicity and increases the proportion of proliferative natural killer (NK) cells in peripheral blood. REGN6569 is applicable for advanced solid malignancies. Isotype control: HY-P99001 .
    REGN6569
  • HY-P991997
    Anti-CD16a Antibody (3G8)

    		Fc Receptor (FcR) Others
    Anti-CD16a Antibody (3G8) is a pan-CD16-specific antibody. Anti-CD16a Antibody (3G8) binds to an epitope overlapping with CD16a’s Fc binding site, inhibiting CD16a-IgG Fc region interactions.Anti-CD16a Antibody (3G8) recognizes CD16a, CD16b, and CD16b-NA1 and NA2 allelotypes expressed by neutrophils .
    Anti-CD16a Antibody (3G8)
  • HY-P992335
    COM503

    		Interleukin Related Cancer
    COM503 is a high-affinity anti-IL18BP human monoclonal antibody with a Kd value of 0.291 pM. COM503 binds to IL18BP, blocks the IL18BP:IL18 interaction, displaces IL18 from preformed complexes, and enhances the activation and function of T cells and NK cells. COM503 induces anti-tumor effects by relieving the activity inhibition of endogenous IL18 in the tumor microenvironment. COM503 can be used for cancer research. The recommended isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
    COM503
  • HY-P992381
    IBI352g4a

    		Drug Derivative Cancer
    IBI352g4a is a humanized IgG1 monoclonal antibody targeting PVRIG (Kd = 0.53 nM) and acts as a PVRIG/PVRL2 inhibitor. The anti-tumor effect of IBI352g4a depends on the binding of its Fc region to FcγR. IBI352g4a binds to the extracellular domains of human and cynomolgus monkey PVRIG, and blocks the PVRIG-PVRL2 interaction. IBI352g4a induces NK cell activation, promotes their degranulation and tumor killing. IBI352g4a can be used in the research of gastric cancer .
    IBI352g4a
  • HY-P992483
    VIS832

    		Transmembrane Glycoprotein Cancer
    VIS832 is an anti-CD138 monoclonal antibody. VIS832 induces antibody-dependent cellular cytotoxicity. VIS832 inhibits the growth of disseminated multiple myeloma tumors in vivo. VIS832 exerts anti-tumor effects on multiple myeloma in combination with Lenalidomide (HY-A0003) or Bortezomib (HY-10227). VIS832 can be used in research related to multiple myeloma .
    VIS832
  • HY-P991998
    Anti-Human/Monkey CD16a Antibody (3G8)

    		Fc Receptor (FcR) Inflammation/Immunology Cancer
    Anti-Human/Monkey CD16a Antibody (3G8) is a monoclonal antibody targeting CD16a. Anti-Human/Monkey CD16a Antibody (3G8) blocks FcγRIII/CD16a, upregulates the metabolic activity of CD16+ cells, downregulates CD87, a poor prognostic marker, and inhibits the engraftment and growth of leukemia cells in acute myeloid leukemia, and rapidly increases platelet counts in immune thrombocytopenia. Anti-Human/Monkey CD16a Antibody (3G8) is applicable to research related to tumor immunology .
    Anti-Human/Monkey CD16a Antibody (3G8)
  • HY-182644
    SMU-Z1

    		Toll-like Receptor (TLR) NF-κB TNF Receptor Interleukin Related Cancer
    SMU-Z1 is a TLR1/2 heterodimer agonist with an EC50 of 4.88 nM. SMU-Z1 activates the NF-κB pathway, triggers pro-inflammatory cytokine production, and induces the generation of TNF-α, IL-1β, IL-6 and NO. SMU-Z1 promotes splenocyte proliferation and upregulates the expression of CD8 +T cells, NK cells and dendritic cells. SMU-Z1 exhibits significant anti-tumor effects in mouse leukemia models. SMU-Z1 can be used for leukemia-related research .
    SMU-Z1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: